Schizophr Res 35(Suppl):S67–S73PubMedCrossRef 32. Warrel DA, Cox TM, Firth JD (2005) Oxford textbook of medicine, vol. 3. 4th edn. Oxford University Press, Oxford 33. Grisso JA, Capezuti E, Schwartz A (1996) Falls as risk factors for fractures. In: Marcus D, Kelsey J, Feldman D (eds) Osteoporosis. Academic, San Diego, pp 599–611 34. I-BET-762 Cummings SR et al (1995) Risk factors for hip CFTRinh-172 price fracture in white women.

Study of osteoporotic fractures research group. N Engl J Med 332(12):767–773PubMedCrossRef 35. Owens DC (1999) A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge University Press, Cambridge 36. Kanis JA et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16(2):155–162PubMedCrossRef 37. Cauley

JA et al (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16(12):1525–1537PubMedCrossRef 38. Alanen HM et al (2006) Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. Int J Geriatr Psychiatry 21(3):288–295PubMedCrossRef 39. Jeste DV et al (2008) ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33(5):957–970PubMedCrossRef 40. Melton LJ III et al (1994) Fracture risk in patients with Alzheimer’s disease. J Am Geriatr DMXAA molecular weight Soc 42:614–619PubMed 41. van Staa TP et al (2002) Utility of medical and drug history in fracture risk prediction among men and women. Bone 31:508–514PubMedCrossRef 42. Whooley MA et al (1999) Depression, falls, and risk of fracture in older women. Arch Intern Med 159(5):484–490PubMedCrossRef 43. Bolton JM et al (2008) Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol next 28(4):384–391PubMedCrossRef”
“Background Malignant gliomas are the most common primary tumors in the brain; they are destructive, invasive, and the most highly vascularized lethal tumors observed in humans. Gliomas are classified into grades I – IV according to their histological degree of malignancy by the

WHO criterion. Despite recent progress in combination therapies, the median survival of patients with glioblastoma (WHO grade IV) is less than 14–15 months [1]. Advances in the treatment of malignant gliomas will require improved understanding of the biology and molecular mechanisms of glioma development and progression. Many studies show that the malignant transformation of glioma is a consequence of the stepwise accumulation of genetic alterations that lead to aberrant regulation of proliferation and differentiation signals and disruption of the apoptotic pathway [1]. Recent research on the molecular basis of gliomas and the implications for targeted therapeutics has focused on the PTEN, EGFR and VEGF signaling pathways [2–4].